The cancer-HIV/AIDS treatment conundrum.
Charlie
C
Schmidt
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D004334:Drug Administration Schedule; D004336:Drug Antagonism; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D011758:Pyrroles / Q000378:metabolism / Q000494:pharmacology; D012307:Risk Factors; D019438:Ritonavir / Q000378:metabolism / Q000494:pharmacology; D000077210:Sunitinib
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D017320:HIV Protease Inhibitors; D007211:Indoles; D011758:Pyrroles; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D019438:Ritonavir; D000077210:Sunitinib